Closed · RFA-IP-22-004 · CFDA 93.083;93.185 · Discretionary
US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
Federal grant opportunity posted by Centers for Disease Control and Prevention - ERA, cataloged on Grants.gov.
- $2M-$9.1M
- Award range
- Closed
- Status
- May 9, 2022
- Close date
- 8
- Expected awards
The verdict
US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings is a closed discretionary listing from Centers for Disease Control and Prevention - ERA that offered $2,000,000 -- $9,100,000 across 8 expected awards. Future funding cycles may be published under the same CFDA number.
- $2M-$9.1M
- award range
- Closed
- application status
- 8
- expected awards
- 93.083;93.185
- CFDA program
Opportunity snapshot. This Grants.gov announcement - US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings - is cataloged under number RFA-IP-22-004 and tied to CFDA assistance listing 93.083;93.185, posted by Centers for Disease Control and Prevention - ERA. Grants.gov currently shows the opportunity as closed, first posted on March 8, 2022 and last updated on March 17, 2022. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is $2,000,000 -- $9,100,000. The agency has projected $107.5 million in total estimated funding for this announcement. It expects to issue 8 awards. If the agency funds the expected 8 awards from the $107.5 million estimated pool, the average award works out to roughly $13.4 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on May 9, 2022. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
$2,000,000 -- $9,100,000
Close Date
May 9, 2022
Electronically submitted applications must be submitted no later than 5:00 pm ET on the listed application due date.
Posted
March 8, 2022
Est. Total Funding
$107,500,000
Expected Awards
8
Instrument
Cooperative Agreement
Description
Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza and novel vaccines, such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed in order to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to support a network of US institutions that can: a) conduct systematic testing for laboratory-confirmed disease due to influenza, SARS-CoV-2 and other respiratory virus infections, b) obtain reliable vaccination information for enrolled patients and c) provide accurate estimates of the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2 and other respiratory viruses, to prevent medically attended influenza-associated illness in the population for whom vaccination is recommended.
Eligibility
Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
Amy Yang AYang@cdc.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Centers for Disease Control and Prevention - ERA
US Travelers Health Research, Surveillance, Communication, and Outreach Network
Emerging Infections Network - Research for Preventing, Detecting, and Managing Travel-associated Infectious Diseases
Occupational Safety and Health Training Project Grants (T03)
Occupational Safety and Health Education and Research Centers (T42)
RFA-PS-18-000
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |